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Introduction
Primary peritoneal serous carcinoma (PPSC) is a rare malig-
nancy with exceedingly low prevalence in male patients. The 
male:female ratio ranges from 0.0018 to 0.0045.1 The first 
case of PPSC was described by Swerdlow in 1959 as “papil-
lary tumor with psammoma bodies resembling ovarian carci-
noma . . . arising from the pelvic peritoneum.”2 Since then, 
PPSC has been increasingly recognized as a distinct histo-
pathological entity and the tumor is classified in the same 
manner as its ovarian counterpart as low and high-grade 
serous carcinoma.3–5 In the absence of ovarian primary, it is 
likely that serous carcinomas develop from the epithelium of 
so called “secondary Mullerian system.”3 To our knowledge, 
there are only four cases of PPSC in males previously 
reported in English literature.6–9 In this publication, we aim 
to present the fifth case of PPSC in a male patient with 
molecular analysis of the tumor for the common mutations 
known to be associated with serous type carcinomas.
Case report
We present a case of a 59-year-old asymptomatic non-
smoker male patient. He was previously diagnosed with a 
stage II (T2N0M0) anal cancer (October 2016) and treated 
with Nigro protocol.10 Eight month later (June 2017), the 
patient underwent a CT scan at an outside hospital which 
showed omental thickening and ascites. Cytopathological 
analysis of the ascites fluid at the outside hospital revealed 
fragmented fibroadipose tissue with marked desmoplastic 
stroma, ducto-glandular structures lined by cuboidal and 
low columnar epithelium and rare psammoma bodies.
The subsequent diagnostic laparoscopy at our institution 
revealed about 2–3 L of ascites fluid and multiple peritoneal 
implants on various peritoneal surfaces, particularly overly-
ing the bladder. There were some smaller discrete implants 
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overlying different portions of the small bowel, its mesen-
tery and right diaphragm. The implants were biopsied, and 
the microscopic examination showed multiple nests of 
medium-sized malignant tumor cells infiltrating fibroadi-
pose stroma with characteristic retraction artifact. The tumor 
cells were organized in micropapillary pattern and showed 
moderate amount of cytoplasm and hyperchromatic nuclei. 
Numerous psammoma bodies were noted. The surrounding 
stroma had a prominent desmoplastic response (Figure 1). 
Immunohistochemistry showed strong staining for CK7, 
PAX8, BerEP4, IMP3, and focal patchy positivity for p53 
(wild type). The tumor cells were negative for CK20, CK 
5/6, WT1, calretinin, TTF-1, thyroglobulin, D2-40, mCEA, 
ER, PR, CDX2 (Figure 2). Ki67 index was estimated as 
10%–15%. Morphologic and immunophenotypic character-
istic of the tumor were suggestive of a low-grade serous 
papillary carcinoma of the Müllerian origin despite of the 
fact that the patient is male. Further clinical workup did not 
reveal other definitive site of origin and no additional abnor-
malities suggesting of its primary peritoneal origin.
Immunohistochemical studies showed no loss of mis-
match repair proteins (MLH1, MSH2, MSH6, and PMS2). 
Tumor microdissection was done, and next generation 
sequencing studies were performed in September 2017 
using Ion Cancer Panels (Thermo Fisher Scientific, Thermo 
Fisher Scientific Inc., Waltham, MA, USA) and amplicon 
sequencing was done based on manufacturers protocol. 
Molecular analysis revealed no copy number alterations. We 
identified pQ1228X stop codon mutation of SF3B1 gene of 
7% of the tumor cells. Wild type variants of the following 
genes were identified: ABL1, AKT1, ALK, APC, ARID1A, 
ARID2, ATM, ATRX, BAX, BCL2L1, BRCA2, BRAF, 
BTG2, CCND1, CCND3, CCNE1, CDH1, CDKN1A, 
CDKN2A, CREBBP, CSF1R, CTNNB1, DAXX, DCC, 
E2F3/SOX4, EGFR, ELF3, EP300, EPC1, ERBB1, ERBB2, 
ERBB3, ERBB4, ERCC2, EZH2, FANCA, FAT4, FBXW7, 
FGFR1, FGFR2, FGFR3, FLT3, FOXA1, FOXQ1, GNA11, 
GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, 
JAK3, KDM6A, KDR, KIT, KLF5, KMT2A, KRAS, 
LKB1, LRP1B, MAGEA6, MAP2K4, MAPK8IP3, MCL1 
MDM2, MEN1, MET, MLH1, MLL1, MLL2, MLL3, MPL, 
MYC, MYCL1, NCOR1, NF1, NFE2L2, NOTCH1, 
NOTCH3, NPM1, NRAS, P24, PALB2, PAIP1, PDGFRA, 
PIK3CA, PIK3R1, PKD1, PPARG, PRSS1, PTEN, 
PTPN11, PVRL4, R2, RB1, RET, RHOA, RHOB, RICTOR, 
RXRA, SF3B1, SLC16A4, SMAD4, SMARCB1, SMO, 
SRC, STAG2, TERT, TGFBR1, TGFBR2, TSC1, TSC2, 
TP53, TXNIP, NALCN, VEGFR, YAP1, YMHAZ, 
ZFP36L1, ZIM2, ZNF703.
Three months later the patient developed tumor recur-
rences at the trochar sites from his laparoscopy and possi-
ble pleural metastasis. He had received two cycles of 
paclitaxel and carboplatin therapy. He is currently stable 
and awaiting additional course of chemotherapy.
Discussion
Developmental aspects of primary peritoneal serous carci-
noma (PPSC) are not fully uncovered. Though infrequent, 
PPSC is considerably more common in female patients due 
to its presumable development from persistent peritoneal 
rests of Müllerian epithelium (“secondary Müllerian 
system”).3,11 One can speculate that male PPSC can also 
arise from the epithelial remnants that did not convolute dur-
ing ontogenesis due to abnormal focal resistance to Müllerian 
inhibiting factor. Serosal surfaces of the testis is a known site 
for primary serous-type tumors in males and the origin of 
these anatomically related tumors remains unclear as well. 
Figure 1. Hematoxylin-eosin stain demonstrating histological features of low grade serous carcinoma: (a) the tumor cells, 
organized in nests with micropapillary pattern and characteristic retraction artifacts. Psammoma bodies are noted (×100 
magnification) and (b) low grade nuclear atypia in tumor cells seen on higher magnification (×400 magnification).
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Another exceedingly rare type Müllerian type tumor clear 
cell adenocarcinoma arising from persistent Müllerian duct 
has been previously reported in male genitourinary tract.12
Diagnostic challenges of PPSC in male patients stem 
from the extreme rarity of the tumor. Diagnostic criteria for 
PPSC in males are not clear yet and presumably similar to 
those in PPSC in female patient. It is extremely important to 
rule out possible primary sites before a diagnosis of PPSC is 
rendered. PPSC in females share histopathological similari-
ties with adnexal serous carcinomas and therefore can be 
divided into two distinguishable groups of low- and high-
grade tumors.3,5 Most of the case reports of PPSC in males 
follow the same classification.9 Table 1 summarizes all 
PPSC cases in male patients reported in English literature.
Morphologically, the tumors are represented by com-
plex papillary architecture, varying cytological atypia and 
psammoma bodies. One of four published PPSC cases in 
males was not graded; two cases presented as high grade, 
but p53 stain was not performed. Limited immunopheno-
typical characterization of three cases did not completely 
rule out other possibilities. The most complete immunophe-
notypic analysis was done by Xu et al.9 Our case of PPSC 
underwent a comprehensive immunohistological workup 
with positive PAX8 and wild-type p53 staining that was 
most consistent with low-grade serous carcinoma.
Differential diagnosis for PPSC in males would include 
malignant mesothelioma and non-Müllerian metastatic carci-
nomas that can share similar morphological features. A recent 
study indicated that PAX8 can be expressed both in benign 
and malignant mesothelial cells.13 This study showed that the 
expression of PAX8 is significantly more common in female 
patients. Importantly, in male patients, no cases with diffuse 
PAX8 positive staining in mesothelial cells were reported. 
PAX8 is a very useful but not the single immunohistochemi-
cal marker that aids the diagnosis. Malignant mesothelioma is 
usually WT-1, calretinin and D2-40 positive. However, WT-1 
cannot be reliably used for differential diagnosis as it was 
found to be positive in male PPSC.9 Urothelial micropapillary 
carcinoma shows positive immunostaining for CK7, CK20, 
and uroplakin that were not seen in our case.
Molecular characteristics of ovarian serous carcinoma 
are well-studied. TP53 mutation is a hallmark of ovarian 
serous carcinomas and is found at significantly higher rate 
in high-grade tumors defining a distinct molecular pathway 
for the later. Additional molecular alterations include KRAS, 
BRAF, NRAS, MSH2 mutations in low-grade tumors and 
BRCA, BARD1, BRIP1, CHEK2, MRE11A, PALB2, 
RAD50, RAD51C mutations, MYC, CCNE1, NOTCH3 
amplifications in high-grade carcinomas.14–16 PPSC in 
females is characterized by the similar molecular profile 
such as loss of heterozygosity at chromosomal loci and 
overexpression of HER2 and BRCA mutations (~40% 
cases).17,18 A whole exome sequencing of a single case of 
female high-grade PPSC showed BRCA1, BRCA2 muta-
tions as well as TP53, ERBB2, EGFR, KRAS and other 
mutations commonly found in ovarian serous 
Figure 2. Selected immunohistochemical stains demonstrated in tumor cells. Positive staining for CK7, PAX8, BerEP4, and 
negative staining for CK20 and WT-1. Wild-type staining for p53 (×100 magnification).
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cell carcinomas.19 Interestingly, retrospective search of a 
database with 2,673 PPSC cases (including only five male 
cases) found no association with germline mutations of 
BRCA in men with PPSC.1 No molecular analysis was pre-
viously performed on male PPSC tumors. In our case, we 
did not find any common mutations associated with PPSC 
in females; however, it was positive for SF3B1 gene muta-
tion that encodes subunit 1 of the splicing factor 3b protein 
complex. SF3B1 mutations are associated with aberrant pre-
mRNA splicing and are frequently found in myelodysplastic 
syndrome (MDS), chronic lymphocytic leukemia and were 
also reported in ovarian serous carcinomas.20 Although our 
patient has no known diagnosis of MDS, we cannot entirely 
exclude the presence of a clonal hematopoiesis of indeter-
minate potential that interferes with the results.
To our knowledge, this is the fifth published case of 
PPSC in male and first case with molecular analysis per-
formed. While it is not possible based on one case to draw 
a solid conclusion on molecular profile of such tumors in 
males, similarities with ovarian type serous carcinomas 
may suggest same lineage. Further studies of male PPSCs 
with full immunohistochemical work-up and molecular 
analysis are needed to better understand the molecular 
pathogenesis and aid in the diagnosis of this rare entity.
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Table 1. Summary of reported cases of primary peritoneal serous carcinomas in male patients.
Publication Histological grade Age, years PAX8 IHC WT-1 IHC P53 IHC Additional Immunostains
Our case Low 59 + − WT Positive: CK7, BerEP4, 
IMP3
 Negative: CK20, CK 
5/6, Calretinin, TTF-1, 
Thyroglobulin, D2-40, 
mCEA, ER, PR, CDX2
Xu et al.9 Low 58 + + WT Positive: CK7, ER
 Negative: CK20, TTF-1, 
Thyroglobulin, PSA, CK5/6, 
Calretinin
Canbay et al.6 Not reported 63 Not reported Not reported Not reported Positive: CK7, ER
 Negative: CK20, PR, D2-40, 
Mesothelin, Calretinin, 
CDX2, mCEA, CA125
Shmueli et al.8 High 53 Not reported Not reported Not reported Positive: CK7, CK20, 
HMWK, LMWK, EMA, 
CD15
 Negative: ER/PR, mCEA, 
Vimentin
Shah et al.7 High 74 Not reported Not reported Not reported Positive: CK7, CK20, PR, 
CAM5.2, EMA, BerEP4




CDX2: caudal type homeobox 2; CK: cytokeratin; D2-40: podoplanin; EMA: epithelial membrane antigen; ER: estrogen receptor; HMWK: 
highmolecular weight cytokeratin; IHC: immunohistochemistry; IMP3: insulin-like growth factor II messenger ribonucleic acid-binding protein 3; 
LMWK: low molecular weight cytokeratin; mCEA: monoclonal carcino-embryonic antigen; PAX8: paired box gene 8; PR: progesterone receptor; 
PSA: prostate specific antigen; TTF-1: thyroid transcription factor-1; WT: wild type; WT-1: Wilms tumor-1.
Makarenko et al. 5
Informed Consent
Written informed consent was obtained from the patient(s) for 
their anonymised information to be published in this article.
ORCID iD
Vladislav V Makarenko  https://orcid.org/0000-0002-2100-0881
References
 1. Neuhausen SL, Shani H, Boker LK, et al. Primary peritoneal 
serous carcinoma in men: a rare and non-BRCA-associated 
entity. Anticancer Res 2017; 37(6): 3069–3072.
 2. Swerdlow M. Mesothelioma of the pelvic peritoneum resem-
bling papillary cystadenocarcinoma of the ovary; case report. 
Am J Obstet Gynecol 1959; 77(1): 197–200.
 3. Cobb LP, Gaillard S, Wang Y, et al. Adenocarcinoma of Mullerian 
origin: review of pathogenesis, molecular biology, and emerg-
ing treatment paradigms. Gynecol Oncol Res Pract 2015; 2: 1.
 4. Fellay CF, Delaloye J-F and Bauer J. Extraovarian primary 
peritoneal carcinoma. In: Yazid B, René-Olivier M, Mahmut 
O (eds) Management of rare adult tumours. Paris: Springer 
Publishing Company, 2010, pp.279–292.
 5. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO clas-
sification of tumours of female reproductive organs. 4th ed. 
Lyon: International Agency for Research on Cancer, 2014.
 6. Canbay E, Ishibashi H, Sako S, et al. Photodynamic detec-
tion and management of intraperitoneal spreading of primary 
peritoneal papillary serous carcinoma in a man: report of a 
case. Surg Today 2014; 44(2): 373–377.
 7. Shah IA, Jayram L, Gani OS, et al. Papillary serous car-
cinoma of the peritoneum in a man: a case report. Cancer 
1998; 82(5): 860–866.
 8. Shmueli E, Leider-Trejo L, Schwartz I, et al. Primary papil-
lary serous carcinoma of the peritoneum in a man. Ann Oncol 
2001; 12(4): 563–567.
 9. Xu JW, Weisman P and Loeffler A. Primary peritoneal low-
grade serous carcinoma in a man: a case report and review of 
the literature. Hum Pathol Case Rep 2017; 9: 1–4.
 10. Nigro ND, Vaitkevicius VK, Buroker T, et al. Combined 
therapy for cancer of the anal canal. Dis Colon Rectum 1981; 
24(2): 73–75.
 11. Li J, Fadare O, Xiang L, et al. Ovarian serous carcinoma: 
recent concepts on its origin and carcinogenesis. J Hematol 
Oncol 2012; 5: 8.
 12. Shinmura Y, Yokoi T and Tsutsui Y. A case of clear cell 
adenocarcinoma of the mullerian duct in persistent muller-
ian duct syndrome: the first reported case. Am J Surg Pathol 
2002; 26(9): 1231–1234.
 13. Chapel DB, Husain AN, Krausz T, et al. PAX8 expression in 
a subset of malignant peritoneal mesotheliomas and benign 
mesothelium has diagnostic implications in the differential 
diagnosis of ovarian serous carcinoma. Am J Surg Pathol 
2017; 41(12): 1675–1682.
 14. Cancer Genome Atlas Research, N. Integrated genomic 
analyses of ovarian carcinoma. Nature 2011; 474(7353): 
609–615.
 15. Jones S, Wang TL and Kurman RJ. Low-grade serous car-
cinomas of the ovary contain very few point mutations. J 
Pathol 2012; 226(3): 413–420.
 16. Kurman RJ. Origin and molecular pathogenesis of ovarian 
high-grade serous carcinoma. Ann Oncol 2013; 24 Suppl 10: 
x16–21.
 17. Iavazzo C, Gkegkes ID and Vrachnis N. Primary peritoneal 
cancer in BRCA carriers after prophylactic bilateral sal-
pingo-oophorectomy. J Turk Ger Gynecol Assoc 2016; 17(2): 
73–76.
 18. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and 
primary peritoneal carcinomas associated with BRCA muta-
tions. J Clin Oncol 2003; 21(22): 4222–4227.
 19. Cheng Z, Yang W, Guo J, et al. Genetic landscape of a case 
of extraovarian peritoneal serous papillary carcinoma. Oncol 
Lett 2016; 12(4): 2395–2402.
 20. Kesarwani AK, Ramirez O, Gupta AK, et al. Cancer-
associated SF3B1 mutants recognize otherwise inaccessi-
ble cryptic 3’ splice sites within RNA secondary structures. 
Oncogene 2017; 36(8): 1123–1133.
